Pheno-MYCN maps the morphological footprint of MYCN amplification in paediatric neuroblastoma
- 1The Institute of Cancer Research
Abstract
MYCN amplification and segmental chromosomal abnormalities have long been prognostic markers in paediatric neuroblastoma, and are often accompanied by morphological changes that portend high-risk disease. Yet quantitative morphological assessment is limited to countable features, such as the mitosis-karyorrhexis index. Other high-risk features, such as nuclear size, pleomorphism and anaplasia, lack formal criteria. This leaves a gap: current simple pathology metrics cannot capture, or localise, the full morphological landscape of high-risk biology, such as disease driven by MYCN. Seeking high-risk cases that standard criteria may miss, we developed Pheno-MYCN, a weakly supervised framework linking slide-level MYCN prediction on 189 H&E whole-slide images to interpretable phenotypic sub-populations that expert review mapped to neuroblastoma morphologies. The aim is not a stronger classifier, but to reveal the morphological basis of MYCN prediction. Cell-level profiling found MYCN-associated differences across sub-populations. Amplified tumour was densely cellular but disorganised, with less connected networks, lower cellular diversity and greater abundance of haemorrhagic and acellular necrotic regions. MYCN-amplified-like tissue was identifiable per slide from these features alone (AUC 0.93-1.00, leave-one-slide-out) and traced as a continuous gradient within tumours. Thus MYCN amplification leaves a concrete, interpretable footprint, readable and localisable on routine H&E.
Related
- The role of personalised medicine in treating high-risk neuroblastoma in paediatric patients.
- Effect of a Phenotype-Tailored Lifestyle Intervention on Caloric Intake and Macronutrient Composition in Adults with Obesity: A Secondary Analysis of the PHENO-Diet Trial
- Pheno+: An Electronic Health Record-Integrated, Clinician-in-the-Loop Application for Efficient Phenotyping in Clinical Genomics
- Usability and workflow implications of an electronic health record-integrated tool for automated phenotyping: Formative evaluation of Pheno+
- Digital Footprint and Audience Engagement Among Infectious Diseases Medical Educators on TikTok
BibTeX
@misc{chai2026phenomycn,
title = {{Pheno-MYCN maps the morphological footprint of MYCN amplification in paediatric neuroblastoma}},
author = {B. Chai and O. Fourkioti and R. Naidoo and M. De Vries and S. Waqar Ahmed and T. Jacques and S. George and L. Chesler and J. C. Hutchinson and C. Bakal},
howpublished = {bioRxiv},
year = {2026},
month = aug,
doi = {10.64898/2026.08.20.745848},
url = {https://www.biorxiv.org/content/10.64898/2026.08.20.745848v2},
note = {CC BY},
}
RIS
TY - UNPB
TI - Pheno-MYCN maps the morphological footprint of MYCN amplification in paediatric neuroblastoma
AU - B. Chai
AU - O. Fourkioti
AU - R. Naidoo
AU - M. De Vries
AU - S. Waqar Ahmed
AU - T. Jacques
AU - S. George
AU - L. Chesler
AU - J. C. Hutchinson
AU - C. Bakal
PY - 2026
DA - 2026/08/20
PB - bioRxiv
DO - 10.64898/2026.08.20.745848
UR - https://www.biorxiv.org/content/10.64898/2026.08.20.745848v2
AB - MYCN amplification and segmental chromosomal abnormalities have long been prognostic markers in paediatric neuroblastoma, and are often accompanied by morphological changes that portend high-risk disease. Yet quantitative morphological assessment is limited to countable features, such as the mitosis-karyorrhexis index. Other high-risk features, such as nuclear size, pleomorphism and anaplasia, lack formal criteria. This leaves a gap: current simple pathology metrics cannot capture, or localise, the full morphological landscape of high-risk biology, such as disease driven by MYCN. Seeking high-risk cases that standard criteria may miss, we developed Pheno-MYCN, a weakly supervised framework linking slide-level MYCN prediction on 189 H&E whole-slide images to interpretable phenotypic sub-populations that expert review mapped to neuroblastoma morphologies. The aim is not a stronger classifier, but to reveal the morphological basis of MYCN prediction. Cell-level profiling found MYCN-associated differences across sub-populations. Amplified tumour was densely cellular but disorganised, with less connected networks, lower cellular diversity and greater abundance of haemorrhagic and acellular necrotic regions. MYCN-amplified-like tissue was identifiable per slide from these features alone (AUC 0.93-1.00, leave-one-slide-out) and traced as a continuous gradient within tumours. Thus MYCN amplification leaves a concrete, interpretable footprint, readable and localisable on routine H&E.
ER -